SB 180: Gene therapy kits: advisory notice and labels.
- Session Year: 2019-2020
- House: Senate
- Latest Version Date: 2019-07-30
|
Date
|
Status
|
|---|---|
| Jul 30, 2019 | Chaptered by Secretary of State. Chapter 140, Statutes of 2019. |
| Jul 30, 2019 | Approved by the Governor. |
| Jul 19, 2019 | Enrolled and presented to the Governor at 2 p.m. |
| Jul 5, 2019 | In Senate. Ordered to engrossing and enrolling. |
| Jul 5, 2019 | Read third time. Passed. Ordered to the Senate. |
| Jun 27, 2019 | Read second time. Ordered to consent calendar. |
| Jun 26, 2019 | From committee: Do pass. Ordered to consent calendar. (Ayes 11. Noes 0.) (June 25). |
| May 16, 2019 | Referred to Com. on P. & C.P. |
| May 7, 2019 | In Assembly. Read first time. Held at Desk. |
| May 6, 2019 | Read third time. Passed. (Ayes 38. Noes 0.) Ordered to the Assembly. |
| May 2, 2019 | Read second time and amended. Ordered to third reading. |
| May 1, 2019 | From committee: Do pass as amended. (Ayes 9. Noes 0.) (April 30). |
| Apr 5, 2019 | Set for hearing April 30. |
| Apr 3, 2019 | Re-referred to Com. on JUD. |
| Mar 27, 2019 | From committee with author's amendments. Read second time and amended. Re-referred to Com. on RLS. |
| Feb 6, 2019 | Referred to Com. on RLS. |
| Jan 29, 2019 | From printer. May be acted upon on or after February 28. |
| Jan 28, 2019 | Introduced. Read first time. To Com. on RLS. for assignment. To print. |
|
Date
|
Description
|
Location
|
Votes
|
|
|---|---|---|---|---|
| Jul 5, 2019 | SB 180 Chang Consent Calendar Second Day Regular Session | Assembly Floor |
Passed |
|
| Jun 25, 2019 | Do pass. To Consent Calendar. | Assembly Standing Committee on Privacy and Consumer Protection |
Passed |
|
| May 6, 2019 | Senate 3rd Reading SB180 Chang | Senate Floor |
Passed |
|
| Apr 30, 2019 | Do pass as amended | Senate Standing Committee on Judiciary |
Passed |
This list shows positions taken on this bill by organizations on the date displayed, which is linked to the original source.
Positions by individuals are not included.
Date of Hearing: June 25, 2019
ASSEMBLY COMMITTEE ON PRIVACY AND CONSUMER PROTECTION
Ed Chau, Chair
ABPCA Bill Id:SB 180 (
Author:Chang) –As Amended Ver:May 2, 2019
SUBJECT: Gene therapy kits: advisory notice and labels
SUMMARY: This bill would require a seller of gene therapy kits to place a notice on their website and on the packaging of the kit stating that the kit is not for self-administration. Specifically, this bill would:
- Prohibit, except as otherwise permitted by federal law, a person from selling a gene therapy kit in this state unless the seller includes a notice on the seller’s internet website in a conspicuous location that is displayed to the consumer prior to the point of sale, and on a label on the package containing the gene therapy kit in plain view and readily legibile, stating that the kit is not for self-administration.
- Define “gene therapy” to mean the administration of genetic material to modify or manipulate the expression of a gene product, or to alter the biological properties of living cells, for therapeutic use.
- Define “gene therapy kit” to mean a product that is sold as a collection of materials for the purpose of facilitating gene therapy experiments, including, but not limited to, a system for the targeted cutting of DNA molecules, such as type II clustered regularly interspaced short palindromic repeats (CRISPR), associated proteins (CRISPR-Cas) systems, including CRISPR-Cas9, as described in Regents of University of California v. Broad Institute, Inc. (2018) 903 F.3d 1286.
- Provide various legislative findings and declarations expressing the intent of the Legislature to ensure the safety of the consumer and the public without stifling innovation, including:
- CRISPR is a new gene editing technology that is a substantial improvement over other gene editing technologies in the ease of use, efficacy, and, in particular, cost. CRISPR is an acronym for “clustered regularly interspaced short palindromic repeats,” which are unique DNA sequences found in some bacteria and other microorganisms. The most-studied CRISPR system is associated with the Cas9 protein and is known as CRISPR-Cas9. During 2012 and 2013, researchers modified CRISPR-Cas9 to serve as an effective and efficient technology for editing the genomes of plants, animals, and microorganisms. Many in the scientific community believe CRISPR-Cas9 has revolutionized gene editing with its simplicity, low cost relative to other methods of gene editing, and creation of new research opportunities.
- CRISPR has the potential to offer revolutionary advancements in the investigation, prevention, and treatment of diseases, especially those with limited or no effective treatments. There has been significant research using CRISPR to treat diabetes, malaria, and sickle cell disease, among others.
- However, there are concerns within the science community on the amateur use of this innovative technology. Currently, there are materials with the capabilities of experimenting with CRISPR technology available for purchase by the public. These “CRISPR kits” have been marketed for self-administration. The affordability and accessibility of these products have benefited educational institutions, but concerns remain about the impact on consumer safety and public health.
- Concerns have also been raised as to what can be created through the amateur use of CRISPR technology. There are instances in which research teams have recreated extinct strains of viral diseases from scratch. The use of CRISPR technology has been subjected to regulations in the European Union. The United States Food and Drug Administration has stated that the sale of gene therapy products with the intent of self-administration is against the law, and cites concerns about safety risks.
EXISTING LAW:
- Establishes the Food and Drug Administration (FDA) in the Department of Health and Human Services. (21 U.S.C. Sec. 393.)
- Tasks the FDA with the mission of promoting the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner. Pursuant to this mission, the FDA is directed to ensure human drugs are safe and effective. (21 U.S.C. Sec. 393.)
- Establishes the Federal Food, Drug, and Cosmetic Act to prohibit the movement in interstate commerce of adulterated and misbranded food, drugs, devices, and cosmetics, and for other purposes. (21 U.S.C. Sec. 301 et seq.)
- Governs the regulation of biological products. (42 U.S.C. Sec. 262.)
FISCAL EFFECT: None. This bill has been keyed nonfiscal by the Legislative Counsel.
COMMENTS:
- Purpose of the bill: This bill seeks to increase consumer protection by ensuring that consumers are informed that gene-therapy kits are not for self-administration. This bill is author-sponsored.
- Author’s Statement: According to the author:
CRISPR-Cas9 technology (CRISPR) has revolutionized gene editing with its simplicity and low cost relative to other methods of gene editing, and creation of new research opportunities. It is anticipated that the global market for gene editing will reach $8.1 billion by 2025. The potential of CRISPR is further exemplified in the rapid increase in CRISPR-related federal research funding and scientific publications. Funding from the National Institutes of Health grew from $5,100,000 in 2011 to $603,000,000 in 2016.
However, there are concerns within the science community [with] the amateur use of this innovative technology. Currently, there are materials with the capabilities of experimenting with CRISPR technology available for purchase by the public. These “DIY CRISPR kits” have been marketed for self-administration. The affordability and accessibility of these products have benefited educational institutions, but concerns remain about the impact on consumer safety and public health. There have been instances caught on video of individuals injecting themselves with CRISPR Cas-9 edited materials.
To ensure consumer protection when purchasing these “DIY CRISPR Kits”, SB 180 requires that all sellers provide a notice on their website that is displayed for the consumer prior to the point of sale, as well as a label on the package containing the CRISPR kit, stating that these kits are not intended for self-administration.
- What is CRISPER-Cas9? CRISPER stands for “clustered regularly interspaced short palindromic repeats” and Cas9 specifies the complementary protein that is used to add, remove, or alter genetic material at specific locations in the genome. As the author points out, this method of genetic editing has the potential to revolutionize gene editing and to potentially make it practical to edit genes on a large scale. This technology has the potential to cure or mitigate genetic disease (e.g., sickle cell anemia and inherited blindness) and offer new avenues for fighting infectious diseases such as human immunodeficiency virus, or HIV.
CRISPER-Cas9 is not itself genetic material. Instead, it is the catalyst for the removal or replacement of existing genetic material and therefore, must be combined with genetic material to complete gene therapy. Understandably, because of the invasiveness of this therapy and the ability to alter an individual’s cellular makeup, it raises numerous ethical and safety-related questions. One of the questions most often debated is the distinction between editing somatic cells and editing germline cells:
Scientists who work in genetics draw a huge distinction between editing somatic cells and editing germline cells. Somatic cells are those in the body that have already differentiated—lung cells or blood cells or liver cells, for example. Editing the germline, on the other hand, involves altering a sperm, egg, or fertilized embryo. As the embryo develops, any change that was made will be propagated through every cell in the body, including sperm and eggs that are passed on to the next generation. Put simply, it’s altering the function of a body part versus altering you, your children, and your children’s children. (Detwiler, Legal vs. Illegal Gene Editing: Here's What's Banned, and Why (Dec. 4, 2018) Popular Mechanics, <https://www.popularmechanics. com/ science/health/amp25385071/gene-editing-crispr-cas9-legal/> [as of Jun. 20, 2019].)
Despite the ethical and safety concerns raised by this process, gene therapy kits can be useful for small-scale demonstrations and non-human experimentation in classrooms and other educational settings. Accordingly, this bill does not seek to ban the sale of these kits in this state, but instead seeks to ensure that they are used safely by informing consumers, prior to the point of sale and again upon receipt of the kit itself, that gene therapy kits are not for self-administration.
- Self-administration of gene therapy: In 2017, a few companies began selling and advocating for the use of CRISPER-Cas9 kits by “bio hackers,” or individuals willing to manipulate their bodies for science to hasten the testing and development of gene therapy treatments. Advocates argued that by democratizing the process of testing gene therapies, the promised advancements could be realized more quickly and more economically than by following the typical FDA testing and approval process. The movement seemingly reached a crescendo in 2018 with several high-profile instances of individual bio hackers self-administering gene therapy treatments on live video or at live events. The FDA quickly issued a response to these events stating:
Gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. Gene therapies offer the potential to treat diseases or conditions for which no or few treatments exist. They are being studied to treat cancer as well as genetic, infectious, and other diseases. FDA considers any use of CRISPR/Cas9 gene editing in humans to be gene therapy.
Gene therapy products are regulated by the FDA’s Center for Biologics Evaluation and Research (CBER). Clinical studies of gene therapy in humans require the submission of an investigational new drug application (IND) prior to their initiation in the United States, and marketing of a gene therapy product requires submission and approval of a biologics license application (BLA). […] FDA has also approved certain gene therapy products.
FDA is aware that gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved.
Consumers are cautioned to make sure that any gene therapy they are considering has either been approved by FDA or is being studied under appropriate regulatory oversight. Information About Self-Administration of Gene Therapy (Nov. 21, 2017) FDA, <https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapy products/ucm586343.htm.> [as of Jun. 20,2019].)
Consistent with these FDA warnings, this bill would prohibit a person from selling a gene therapy kit unless the person includes a conspicuous notice on their internet website that is displayed to the consumer prior to the point of sale, and on a readily legible label on the package containing the gene therapy kit, stating that the kit is not for self-administration. These notices are designed to help inform consumers about the proper uses of these products may even help alert them to the potential dangers associated with the self-administration of gene therapy.
Staff notes that given federal jurisdiction over biologics and gene therapies and the declaration that the FDA considers the use of gene editing technologies such as CRISPR-Cas9 in humans to be gene therapy, there has been some concern that this bill may be federally preempted. However, because the notices required by this bill align with the FDA’s position that the sale of these kits for self-administration is illegal, sellers should be able to comply with both this bill and federal law. Accordingly, this bill does not obstruct federal law and is likely not preempted. (See Wyeth v. Levine (2009) 555 U.S. 555.)
REGISTERED SUPPORT / OPPOSITION:
Support
None on file
Opposition
None on file
Analysis Prepared by: David Watson / P. & C.P. / (916) 319-2200
Office of Senate Floor Analyses (916) 651-1520 Fax: (916) 327-4478 | SB 180 |
THIRD READING
Bill No: SB 180
Amended: 5/2/19
SENATE JUDICIARY COMMITTEE: 9-0, 4/30/19
AYES: Jackson, Borgeas, Allen, Caballero, Jones, Monning, Stern, Umberg, Wieckowski
SUBJECT: Gene therapy kits: advisory notice and labels
DIGEST:
This bill requires a seller of gene therapy kits to place a notice on their Web site and on the packaging of the kit that states the kit is not for self-administration.
Existing law:
- Establishes the Food and Drug Administration (FDA) in the Department of Health and Human Services. (21 U.S.C. § 393.)
- Tasks the FDA with the mission to promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner. Pursuant to this mission, the FDA is directed to ensure human drugs are safe and effective. (21 U.S.C. § 393.)
- Establishes the Federal Food, Drug, and Cosmetic Act to prohibit the movement in interstate commerce of adulterated and misbranded food, drugs, devices, and cosmetics, and for other purposes. (21 U.S.C. § 301 et seq.)
- Governs the regulation of biological products. (42 U.S.C. § 262.)
This bill:
- Defines “gene therapy” to mean the administration of genetic material to modify or manipulate the expression of a gene product, or to alter the biological properties of living cells, for therapeutic use.
- Defines “gene therapy kit” to mean a product that is sold as a collection of materials for the purpose of facilitating gene therapy experiments, including, but not limited to, a system for the targeted cutting of DNA molecules, such as type II clustered regularly interspaced short palindromic repeats (CRISPR), associated proteins (CRISPR-Cas) systems, including CRISPR-Cas9, as described in Regents of University of California v. Broad Institute, Inc. (2018) 903 F.3d 1286.
- Prohibits, except as permitted by federal law, a person from selling a gene therapy kit in this state unless the seller includes a notice on the seller’s Internet Web site in a conspicuous location that is displayed to the consumer prior to the point of sale, and on a label on the package containing the gene therapy kit, in plain view and readily legible, stating that the kit is not for self-administration.
Background
Gene therapy carries with it great potential for the future treatment and prevention of various diseases. One new gene editing technology is CRISPR-Cas9. CRISPR-Cas9 is “faster, cheaper, more accurate, and more efficient than other existing genome editing methods.”[1] This new technology is now widely available for professional researchers as well as amateur hobbyists. Recent reports of “biohackers” injecting themselves with DNA encoding for CRISPR highlight the concerns with the use of this revolutionary technology on humans.
This bill requires a person selling a gene therapy kit, such as CRISPR-Cas9 kits, in California to include a notice on their Web site that is displayed to the consumer prior to the point of sale, and to place the notice on a label on the package containing the gene therapy kit, stating that the kit is not for self-administration. There are no requirements for specific location, size, or language.
Comments
According to the author:
CRISPR-Cas9 technology (CRISPR) has revolutionized gene editing with its simplicity and low cost relative to other methods of gene editing, and creation of new research opportunities. It is anticipated that the global market for gene editing will reach $8.1 billion by 2025. The potential of CRISPR is further exemplified in the rapid increase in CRISPR-related federal research funding and scientific publications. Funding from the National Institutes of Health grew from $5,100,000 in 2011 to $603,000,000 in 2016.
However, there are concerns within the science community on the amateur use of this innovative technology. Currently, there are materials with the capabilities of experimenting with CRISPR technology available for purchase by the public. These “DIY CRISPR kits” have been marketed for self-administration. The affordability and accessibility of these products have benefited educational institutions, but concerns remain about the impact on consumer safety and public health. There have been instances caught on video of individuals injecting themselves with CRISPR-Cas9 edited materials.
To ensure consumer protection when purchasing these “DIY CRISPR Kits”, SB 180 requires that all sellers provide a notice on their website that is displayed for the consumer prior to the point of sale, as well as a label on the package containing the CRISPR kit, stating that these kits are not intended for self-administration.
Gene Therapy, CRISPR-Cas9, and Federal Oversight
According to the United States National Library of Medicine:
Genome editing (also called gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome. Several approaches to genome editing have been developed.
A recent one is known as CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate, and more efficient than other existing genome editing methods.
CRISPR-Cas9 was adapted from a naturally occurring genome editing system in bacteria. The bacteria capture snippets of DNA from invading viruses and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to "remember" the viruses (or closely related ones). If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses' DNA. The bacteria then use Cas9 or a similar enzyme to cut the DNA apart, which disables the virus. [2]
The FDA regulates both biologics and chemical drugs. The Center for Biologics Evaluation and Research (CBER) within FDA regulates, among other things, gene therapy products.[3] CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.[4]
According to the FDA:
Gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. Gene therapies offer the potential to treat diseases or conditions for which no or few treatments exist. They are being studied to treat cancer as well as genetic, infectious, and other diseases. FDA considers any use of CRISPR/Cas9 gene editing in humans to be gene therapy.[5]
Despite this assertion of jurisdiction, many have argued that government oversight is woefully inadequate and is failing to keep pace with technologies such as CRISPR-Cas9.[6]
Self-Administration of Gene Therapy
Gene-editing techniques and technology, including CRISPR-Cas9, have become increasingly accessible and widely shared.
There are clearly many questions, both ethical and safety-related, that are triggered by such technologies. One line that has been drawn differentiates editing somatic versus germline cells:
Scientists who work in genetics draw a huge distinction between editing somatic cells and editing germline cells. Somatic cells are those in the body that have already differentiated—lung cells or blood cells or liver cells, for example.
Editing the germline, on the other hand, involves altering a sperm, egg, or fertilized embryo. As the embryo develops, any change that was made will be propagated through every cell in the body, including sperm and eggs that are passed on to the next generation. Put simply, it’s altering the function of a body part versus altering you, your children, and your children’s children.[7]
An international summit was convened to address the rise of these technologies and specifically the issues identified above:
The field of genetics is moving rapidly with new techniques that focus on DNA manipulation in vivo resulting in the alteration of genes to correct mutations, introduce new genetic information, and remove specific DNA sequences. Zinc-Finger Nucleases, TALENs and CRISPR/Cas9 are a few of the genome editing tools that are now available to the scientific research community. To address the societal issues surrounding genome editing, the International Summit on Human Gene Editing, hosted by the scientific academies of China, the United Kingdom and the U.S. was held in December 2015 in Washington DC. The summit concluded that somatic therapies based on genome editing should proceed under the existing FDA regulatory framework, but editing the human germline would be irresponsible to pursue at this time.[8]
Recently, the FDA gave approval to Editas Medicine to begin clinical trials using CRISPR-Cas9 to treat an inherited form of childhood blindness.[9] This marks the first in-body CRISPR medicine testing approved by the FDA. This is in addition to other somatic therapies, focusing on other diseases, such as beta-thalassemia and sickle cell disease.
Despite these authorized therapies and clinical trials, concerns continue about the use of this technology outside professional environments and outside ethical guidelines. Concerns have risen as high-profile bio-hacking stunts have involved biohackers injecting themselves with DNA modified with CRISPR technology.[10] Even more concerning, it was widely reported in 2018, that a Chinese researcher claims to have successfully used CRISPR-Cas9 technology to genetically edit embryos outside of industry-accepted protocols, resulting in the birth of twin girls with altered DNA.[11] In addition, concerns about the possible public health consequences of widespread use of gene therapies have been raised. One of the more infamous biohackers has warned that the increased use of gene therapy kits, made widely available to consumers, is immensely troubling: “There’s no doubt in my mind that somebody is going to end up hurt eventually.”[12]
This bill addresses the increasing prevalence of these DIY-gene therapy kits that are being sold online, including some that are specifically advertised as being intended for self-administration. The FDA has identified the issue and made the following pronouncement:
FDA is aware that gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved.[13]
This bill prohibits a person from selling a gene therapy kit, as defined, unless the person includes a notice on their internet website that is displayed to the consumer prior to the point of sale, and on a label on the package containing the gene therapy kit, stating that the kit is not for self-administration. These notices could help inform consumers about the proper uses of these products and possibly alert them to the potential dangers.
It should be noted that given the assertion of federal jurisdiction over biologics and gene therapies, and the declaration that the FDA considers use of gene editing technologies such as CRISPR-Cas9 in humans to be gene therapy, there is some concern that this bill may be susceptible to federal preemption. However, the notices required by this statute track with the FDA’s pronouncement that the sale of these kits for self-administration is illegal. Therefore, sellers are able to comply with both this bill and federal law, and this bill does not obstruct the applicable federal law. (See Wyeth v. Levine (2009) 555 U.S. 555.)
FISCAL EFFECT: Appropriation: No Fiscal Com.: No Local: No
None received
None received
Prepared by: Christian Kurpiewski / JUD. / (916) 651-4113
5/3/19 13:59:51
**** END ****
Genetics Home Reference, What are genome editing and CRISPR-Cas9? (April 2, 2019) National Institute of Health, https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting [as of Apr. 15, 2019], all further URL citations were available as of April 15, 2019. ↑
Ibid. ↑
Judith A. Johnson, Biologics and Biosimilars: Background and Key Issues (October 27, 2017) Congressional Research Service, https://fas.org/sgp/crs/misc/R44620.pdf. ↑
Cellular & Gene Therapy Products (February 4, 2019) FDA, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm. ↑
Information About Self-Administration of Gene Therapy (November 21, 2017) FDA, https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm586343.htm. ↑
Brooke Borel, The U.S. Regulations for Biotechnology Are Woefully Out of Date (April 21, 2017) Slate, https://slate.com/technology/2017/04/u-s-biotechnology-regulations-are-woefully-out-of-date.html. ↑
Jacqueline Detwiler, Legal vs. Illegal Gene Editing: Here's What's Banned, and Why (December 4, 2018) Popular Mechanics, https://www.popularmechanics.com/science/health/amp25385071/gene-editing-crispr-cas9-legal/. ↑
Therapeutic Cloning and Genome Modification (March 16, 2018) FDA, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm2007205.htm. ↑
Cormac Sheridan, Go-ahead for first in-body CRISPR medicine testing (December 14, 2018) Nature Biotechnology, https://www.nature.com/articles/d41587-018-00003-2. ↑
Emily Baumgaertner, As D.I.Y. Gene Editing Gains Popularity, ‘Someone Is Going to Get Hurt’ (May 14, 2018) New York Times, https://www.nytimes.com/2018/05/14/science/biohackers-gene-editing-virus.html; Sarah Zhang, A Biohacker Regrets Publicly Injecting Himself With CRISPR (February 20, 2018) The Atlantic, https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/. ↑
Marilynn Marchione, Chinese researcher claims first gene-edited babies (November 26, 2018) Associated Press, https://www.apnews.com/4997bb7aa36c45449b488e19ac83e86d. ↑
Sarah Zhang, A Biohacker Regrets Publicly Injecting Himself With CRISPR (February 20, 2018) The Atlantic, https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/. ↑
Information About Self-Administration of Gene Therapy (November 21, 2017) FDA, https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm586343.htm. ↑
Senator Hannah-Beth Jackson, Chair
2019-2020 Regular Session
Bill No: SB 180 (Author:Chang)
Version: March 27, 2019
Hearing Date: April 30, 2019
Fiscal: No
Urgency: No
Consultant: CK
SUBJECT
Gene therapy kits: advisory notice and labels
DIGEST
This bill requires a seller of gene therapy kits to place a notice on their website and on the packaging of the kit that states the kit is not for self-administration.
EXECUTIVE SUMMARY
Gene therapy carries with it great potential for the future treatment and prevention of various diseases. One new gene editing technology is CRISPR-Cas9. CRISPR-Cas9 is “faster, cheaper, more accurate, and more efficient than other existing genome editing methods.”[1] This new technology is now widely available for professional researchers as well as amateur hobbyists. Recent reports of “biohackers” injecting themselves with DNA encoding for CRISPR highlight the concerns with the use of this revolutionary technology on humans.
This bill requires a person selling a gene therapy kit, such as CRISPR-Cas9 kits, in California to include a notice on their website that is displayed to the consumer prior to the point of sale, and to place the notice on a label on the package containing the gene therapy kit, stating that the kit is not for self-administration. There are no requirements for specific location, size, or language.
This bill is author sponsored. There is no known support or opposition.
PROPOSED CHANGES TO THE LAW
Existing law:
- Establishes the Food and Drug Administration (FDA) in the Department of Health and Human Services. (21 U.S.C. § 393.)
- Tasks the FDA with the mission to promote the public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products in a timely manner. Pursuant to this mission, the FDA is directed to ensure human drugs are safe and effective. (21 U.S.C. § 393.)
- Establishes the Federal Food, Drug, and Cosmetic Act to prohibit the movement in interstate commerce of adulterated and misbranded food, drugs, devices, and cosmetics, and for other purposes. (21 U.S.C. § 301 et seq.)
- Governs the regulation of biological products. (42 U.S.C. § 262.)
This bill:
- Defines “gene therapy” to mean the administration of genetic material to modify or manipulate the expression of a gene product, or to alter the biological properties of living cells, for therapeutic use.
- Defines “gene therapy kit” to mean a product that is sold as a collection of materials for the purpose of facilitating gene therapy experiments, including, but not limited to, a system for the targeted cutting of DNA molecules, such as type II clustered regularly interspaced short palindromic repeats (CRISPR), associated proteins (CRISPR-Cas) systems, including CRISPR-Cas9, as described in Regents of University of California v. Broad Institute, Inc. (2018) 903 F.3d 1286.
- Prohibits, except as otherwise permitted by federal law, a person from selling a gene therapy kit in this state unless the seller includes a notice on the seller’s internet website that is displayed to the consumer prior to the point of sale, and on a label on the package containing the gene therapy kit, stating that the kit is not for self-administration.
COMMENTS
- Gene therapy, CRISPR-Cas9, and federal oversight
According to the United States National Library of Medicine:
Genome editing (also called gene editing) is a group of technologies that give scientists the ability to change an organism's DNA. These technologies allow genetic material to be added, removed, or altered at particular locations in the genome. Several approaches to genome editing have been developed.
A recent one is known as CRISPR-Cas9, which is short for clustered regularly interspaced short palindromic repeats and CRISPR-associated protein 9. The CRISPR-Cas9 system has generated a lot of excitement in the scientific community because it is faster, cheaper, more accurate, and more efficient than other existing genome editing methods.
CRISPR-Cas9 was adapted from a naturally occurring genome editing system in bacteria. The bacteria capture snippets of DNA from invading viruses and use them to create DNA segments known as CRISPR arrays. The CRISPR arrays allow the bacteria to "remember" the viruses (or closely related ones). If the viruses attack again, the bacteria produce RNA segments from the CRISPR arrays to target the viruses' DNA. The bacteria then use Cas9 or a similar enzyme to cut the DNA apart, which disables the virus. [2]
The FDA regulates both biologics and chemical drugs. The Center for Biologics Evaluation and Research (CBER) within FDA regulates, among other things, gene therapy products.[3] CBER uses both the Public Health Service Act and the Federal Food Drug and Cosmetic Act as enabling statutes for oversight.[4]
According to the FDA:
Gene therapy is the administration of genetic material to modify or manipulate the expression of a gene product or to alter the biological properties of living cells for therapeutic use. Gene therapies offer the potential to treat diseases or conditions for which no or few treatments exist. They are being studied to treat cancer as well as genetic, infectious, and other diseases. FDA considers any use of CRISPR/Cas9 gene editing in humans to be gene therapy.[5]
Despite this assertion of jurisdiction, many have argued that government oversight is woefully inadequate and is failing to keep pace with technologies such as CRISPR-Cas9.[6]
- Self-administration of gene therapy
Gene-editing techniques and technology, including CRISPR-Cas9, have become increasingly accessible and widely shared.
There are clearly many questions, both ethical and safety-related, that are triggered by such technologies. One line that has been drawn differentiates editing somatic versus germline cells:
Scientists who work in genetics draw a huge distinction between editing somatic cells and editing germline cells. Somatic cells are those in the body that have already differentiated—lung cells or blood cells or liver cells, for example.
Editing the germline, on the other hand, involves altering a sperm, egg, or fertilized embryo. As the embryo develops, any change that was made will be propagated through every cell in the body, including sperm and eggs that are passed on to the next generation. Put simply, it’s altering the function of a body part versus altering you, your children, and your children’s children.[7]
An international summit was convened to address the rise of these technologies and specifically the issues identified above:
The field of genetics is moving rapidly with new techniques that focus on DNA manipulation in vivo resulting in the alteration of genes to correct mutations, introduce new genetic information, and remove specific DNA sequences. Zinc-Finger Nucleases, TALENs and CRISPR/Cas9 are a few of the genome editing tools that are now available to the scientific research community. To address the societal issues surrounding genome editing, the International Summit on Human Gene Editing, hosted by the scientific academies of China, the United Kingdom and the U.S. was held in December 2015 in Washington DC. The summit concluded that somatic therapies based on genome editing should proceed under the existing FDA regulatory framework, but editing the human germline would be irresponsible to pursue at this time.[8]
Recently, the FDA gave approval to Editas Medicine to begin clinical trials using CRISPR-Cas9 to treat an inherited form of childhood blindness.[9] This marks the first in-body CRISPR medicine testing approved by the FDA. This is in addition to other somatic therapies, focusing on other diseases, such as beta-thalassemia and sickle cell disease.
Despite these authorized therapies and clinical trials, concerns continue about the use of this technology outside professional environments and outside ethical guidelines. Concerns have risen as high-profile bio-hacking stunts have involved biohackers injecting themselves with DNA modified with CRISPR technology.[10] Even more concerning, it was widely reported in 2018, that a Chinese researcher claims to have successfully used CRISPR-Cas9 technology to genetically edit embryos outside of industry-accepted protocols, resulting in the birth of twin girls with altered DNA.[11] In addition, concerns about the possible public health consequences of widespread use of gene therapies have been raised. One of the more infamous biohackers has warned that the increased use of gene therapy kits, made widely available to consumers, is immensely troubling: “There’s no doubt in my mind that somebody is going to end up hurt eventually.”[12]
This bill addresses the increasing prevalence of these DIY-gene therapy kits that are being sold online, including some that are specifically advertised as being intended for self-administration. The FDA has identified the issue and made the following pronouncement:
FDA is aware that gene therapy products intended for self-administration and “do it yourself” kits to produce gene therapies for self-administration are being made available to the public. The sale of these products is against the law. FDA is concerned about the safety risks involved.[13]
This bill prohibits a person from selling a gene therapy kit, as defined, unless the person includes a notice on their internet website that is displayed to the consumer prior to the point of sale, and on a label on the package containing the gene therapy kit, stating that the kit is not for self-administration. These notices could help inform consumers about the proper uses of these products and possibly alert them to the potential dangers.
It should be noted that given the assertion of federal jurisdiction over biologics and gene therapies, and the declaration that the FDA considers use of gene editing technologies such as CRISPR/Cas9 in humans to be gene therapy, there is some concern that this bill may be susceptible to federal preemption. However, the notices required by this statute track with the FDA’s pronouncement that the sale of these kits for self-administration is illegal. Therefore, sellers are able to comply with both this bill and federal law, and this bill does not obstruct the applicable federal law. (See Wyeth v. Levine (2009) 555 U.S. 555.)
2. Stated intent of the bill
According to the author:
CRISPR-Cas9 technology (CRISPR) has revolutionized gene editing with its simplicity and low cost relative to other methods of gene editing, and creation of new research opportunities. It is anticipated that the global market for gene editing will reach $8.1 billion by 2025. The potential of CRISPR is further exemplified in the rapid increase in CRISPR-related federal research funding and scientific publications. Funding from the National Institutes of Health grew from $5,100,000 in 2011 to $603,000,000 in 2016.
However, there are concerns within the science community on the amateur use of this innovative technology. Currently, there are materials with the capabilities of experimenting with CRISPR technology available for purchase by the public. These “DIY CRISPR kits” have been marketed for self-administration. The affordability and accessibility of these products have benefited educational institutions, but concerns remain about the impact on consumer safety and public health. There have been instances caught on video of individuals injecting themselves with CRISPR Cas-9 edited materials.
To ensure consumer protection when purchasing these “DIY CRISPR Kits”, SB 180 requires that all sellers provide a notice on their website that is displayed for the consumer prior to the point of sale, as well as a label on the package containing the CRISPR kit, stating that these kits are not intended for self-administration.
3. Additional safeguards and clarity
Generally, when notices are required to be placed on internet websites and packaging, there are clear guidelines on the specific location, size, and language to be used in the notices. At the very least, statutes will generally include provisions requiring notice be prominently displayed and readily legible to ensure the goals of the statute are effectuated. The author has agreed to amend the bill to require the notice be placed in a conspicuous location on the seller’s website and require the label to be in plain view and readily legible on the packaging. This will help ensure that these notices are accessible to consumers and adequately communicated.
SUPPORT
None known
OPPOSITION
None known
RELATED LEGISLATION
Pending: SB 347 (Monning, 2019) requires a safety warning to be placed on certain sugary beverages that states: “STATE OF CALIFORNIA SAFETY WARNING: Drinking beverages with added sugar(s) may contribute to obesity, type 2 diabetes, and tooth decay.” The warning must be prominently displayed and readily legible and must appear in the specified size and format. This bill is in the Senate Appropriations Committee.
Prior: None known
**************
Genetics Home Reference, What are genome editing and CRISPR-Cas9? (April 2, 2019) National Institute of Health, https://ghr.nlm.nih.gov/primer/genomicresearch/genomeediting [as of Apr. 15, 2019], all further URL citations were available as of April 15, 2019. ↑
Ibid. ↑
Judith A. Johnson, Biologics and Biosimilars: Background and Key Issues (October 27, 2017) Congressional Research Service, https://fas.org/sgp/crs/misc/R44620.pdf. ↑
Cellular & Gene Therapy Products (February 4, 2019) FDA, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/default.htm. ↑
Information About Self-Administration of Gene Therapy (November 21, 2017) FDA, https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm586343.htm. ↑
Brooke Borel, The U.S. Regulations for Biotechnology Are Woefully Out of Date (April 21, 2017) Slate, https://slate.com/technology/2017/04/u-s-biotechnology-regulations-are-woefully-out-of-date.html. ↑
Jacqueline Detwiler, Legal vs. Illegal Gene Editing: Here's What's Banned, and Why (December 4, 2018) Popular Mechanics, https://www.popularmechanics.com/science/health/amp25385071/gene-editing-crispr-cas9-legal/. ↑
Therapeutic Cloning and Genome Modification (March 16, 2018) FDA, https://www.fda.gov/BiologicsBloodVaccines/CellularGeneTherapyProducts/ucm2007205.htm. ↑
Cormac Sheridan, Go-ahead for first in-body CRISPR medicine testing (December 14, 2018) Nature Biotechnology, https://www.nature.com/articles/d41587-018-00003-2. ↑
Emily Baumgaertner, As D.I.Y. Gene Editing Gains Popularity, ‘Someone Is Going to Get Hurt’ (May 14, 2018) New York Times, https://www.nytimes.com/2018/05/14/science/biohackers-gene-editing-virus.html; Sarah Zhang, A Biohacker Regrets Publicly Injecting Himself With CRISPR (February 20, 2018) The Atlantic, https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/. ↑
Marilynn Marchione, Chinese researcher claims first gene-edited babies (November 26, 2018) Associated Press, https://www.apnews.com/4997bb7aa36c45449b488e19ac83e86d. ↑
Sarah Zhang, A Biohacker Regrets Publicly Injecting Himself With CRISPR (February 20, 2018) The Atlantic, https://www.theatlantic.com/science/archive/2018/02/biohacking-stunts-crispr/553511/. ↑
Information About Self-Administration of Gene Therapy (November 21, 2017) FDA, https://www.fda.gov/biologicsbloodvaccines/cellulargenetherapyproducts/ucm586343.htm. ↑
Bill Author
Bill Co-Author(s):